Noile-Immune Biotech Inc. (4893) said on Oct. 5 it has received full payment of ¥1.4 million for its 14th series of stock acquisition rights with an exercise price adjustment clause, allotted to Okasan Securities Co., Ltd., covering up to 10 million shares and expected to raise an estimated net ¥1,349.4 million.
The rights were approved by the board on Sept. 18, 2026, and allotted on Oct. 5. The company issued 100,000 units at ¥14 each, with each unit convertible into 100 shares. The company is listed on the Tokyo Stock Exchange Growth market.
| Item | Figure |
|---|---|
| Units issued | 100,000 |
| Issue price | ¥14 per unit (¥1.4 million total) |
| Potential shares | 10 million |
| Initial exercise price | ¥136 |
| Floor exercise price | ¥81 |
| Estimated net proceeds | ¥1,349.4 million |
The initial exercise price of ¥136 equals the TSE closing price on the trading day before the resolution date. The price will be reset to 95% of the TSE closing price on the trading day before each exercise takes effect, rounded down to the nearest yen, whenever that figure differs from the prevailing exercise price by ¥1 or more, subject to the ¥81 floor. There is no cap on the exercise price, and the number of potential shares stays at 10 million even at the floor.
The estimated proceeds assume all rights are exercised at the initial price, net of estimated issuance costs. Actual proceeds will rise or fall with the exercise price and will shrink if rights go unexercised or if the company acquires and cancels them.
Under the allotment agreement, the company may designate periods during which Okasan cannot exercise the rights. While any rights remain outstanding, the company may not issue shares, stock acquisition rights or securities convertible into or granting the right to acquire them for 180 days after the agreement date without Okasan's prior written consent. Transfers of the rights require board approval.
The rights are exercisable from the bank business day following the allotment date, inclusive, through Oct. 5, 2028.
| Hikari Tsushin, Inc. | |
| Offer price | ¥1,000 per common share |
| M&A / TOB | 1 |
| Guidance | 0 |
| Buybacks | 0 |
| Dividends | 0 |
| Capital | 0 |
| Earnings | 0 |
| People | 0 |
Summaries of public disclosures by Japanese listed companies. Not investment advice; accuracy not guaranteed. Figures and dates in the TDnet originals prevail.
本站內容為日本上市公司公開開示之摘要整理，非投資建議，亦不保證正確。數字與日程以 TDnet 原文為準。
本サイトは日本の上場企業の適時開示を要約したものであり、投資助言ではありません。正確性は保証しません。数値・日程は TDnet の原文が優先します。